Reaction
Thrombophlebitis Migrans reporting signals
As of the last recalculation, Thrombophlebitis Migrans appears in 320 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is DURVALUMAB (PRR 71.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Durvalumab | 21 | 71.8 | 71.9 |
| Pembrolizumab | 60 | 45.4 | 45.4 |
| Atezolizumab | 23 | 41.4 | 41.5 |
| Pemetrexed Disodium | 22 | 40.3 | 40.3 |
| Gemcitabine Hydrochloride | 28 | 37.5 | 37.5 |
| Cisplatin | 35 | 32.6 | 32.6 |
| Lenvatinib | 15 | 31.2 | 31.2 |
| Irinotecan Hydrochloride | 6 | 30.9 | 30.9 |
| Pemetrexed | 9 | 28.1 | 28.1 |
| Nivolumab | 37 | 28.0 | 28.0 |
| Ipilimumab | 17 | 27.0 | 27.0 |
| Osimertinib | 12 | 25.3 | 25.3 |
| Fam-Trastuzumab Deruxtecan-Nxki | 3 | 19.5 | 19.5 |